SCHEMBL31048468

SCHEMBL31048468

CC(C)(C)OC(=O)N1CCCCC[C@H]1CO

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
PDE8B O95263 1/20 0.47
HPGD P15428 1/20 0.47
EPHX1 P07099 1/20 0.44
KDM1A O60341 1/20 0.44
ATM Q13315 2/20 0.44
HSD17B10 Q99714 1/20 0.44
EPHX2 P34913 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NR1H2 P55055 1/20 0.41
ALDH1A1 P00352 2/20 0.41
TSHR P16473 1/20 0.40
MEN1 O00255 1/20 0.40
MAPT P10636 1/20 0.40
KMT2A Q03164 1/20 0.40
PREP P48147 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20399730 1.00 POLB (0.50) POLBL3MBTL1PDE8BHPGDEPHX1
SCHEMBL31323435 1.00 POLB (0.50) POLBL3MBTL1PDE8BHPGDEPHX1
SCHEMBL192841 0.98 POLB (0.51) POLBL3MBTL1PDE8BHPGDEPHX1
SCHEMBL282976 0.98 POLB (0.51) POLBL3MBTL1PDE8BHPGDEPHX1
SCHEMBL282977 0.98 POLB (0.51) POLBL3MBTL1PDE8BHPGDEPHX1
SCHEMBL135177 0.94 L3MBTL1 (0.58) POLBL3MBTL1PDE8BHPGDATM
SCHEMBL47049 0.94 L3MBTL1 (0.58) POLBL3MBTL1PDE8BHPGDATM
SCHEMBL133363 0.94 L3MBTL1 (0.58) POLBL3MBTL1PDE8BHPGDATM
SCHEMBL3769601 0.90 HPGD (0.54) POLBL3MBTL1PDE8BHPGDEPHX1
SCHEMBL3769598 0.90 HPGD (0.54) POLBL3MBTL1PDE8BHPGDEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4735438-A2 HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS Merck Patent GmbH (DE) 2026-05-06 EP disclosed
EP-4695260-A1 KRAS MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2026-02-18 EP disclosed
WO-2025006783-A2 HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS MERCK PATENT GMBH (DE) 2025-01-02 WO disclosed
US-20240383922-A1 KRAS Modulating Compounds GILEAD SCIENCES, INC. 2024-11-21 US disclosed
WO-2024215754-A1 KRAS MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2024-10-17 WO disclosed
WO-2024178304-A1 KRAS MODULATORS ALTEROME THERAPEUTICS, INC. (US) 2024-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383922-A1 KRAS Modulating Compounds KRAS, NRAS, HRAS POLB 1907/4885L3MBTL1 2862/4885PDE8B 2214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.